Objective: Prostate cancer is the fourth most common form of cancer in Russia. Given the wide range of luteinising-hormone-releasing hormone agonists (LHRHa) currently available for prostate cancer treatment in Russia it is important to understand relative costs of therapy between agents.

Methods: This cost-minimisation analysis compared 1-, 2-, 3- and 6-monthly preparations of leuprorelin, triptorelin and goserelin acetate. The perspective used was that of the Russian Health Authority, and included costs for drug acquisition, clinic visits and management of adverse events.

Results: Mean annual cost of LHRHa treatment per patient was estimated at 112,435 roubles. The lowest cost treatment option was Eligard® 45 mg (6-month formulation of leuprorelin); the highest cost treatment option was Diphereline™ 3.75 mg (1-month formulation of triptorelin). The main cost drivers were the reported superior efficacy and lower unit cost.

Conclusion: Use of Eligard® 45 mg could potentially reduce prostate cancer treatment costs in Russia.